Nesrin KARAMUSTAFALIOĞLU, Abdullah GENÇ, Tevfik KALELİOĞLU

İkiuçlu bozukluk manik dönemde periferik biyobelirteçler

İkiuçlu bozukluk etiyolojisi tam olarak bilinmeyen kronik bir hastalıktır. Son zamanlarda ikiuçlu bozukluğun patofizyolojisini anlamaya yönelik yapılan çalışmalarda, oksidatif stres, inflamasyon ve nörotrofik faktörler çokça çalışılmış- tır. Bu çalışmalarda bulgular farklılık gösterse de oksidatif stres, inflamatuar ve nörotrofik faktör biyobelirteçlerinde önemli bulgular elde edilmiştir. Bu derlemede ikiuçlu bozukluğun karakteristik dönemlerinden birisi olan manik dönemde serum veya plazmada çalışılan oksidatif stres, inflamasyon ve nörotrofik faktör biyobelirteçleri üzerinde durulacaktır.

Peripheral biomarkers in bipolar disorder manic episode

İkiuçlu bozukluk etiyolojisi tam olarak bilinmeyen kronikbir hastalıktır. Son zamanlarda ikiuçlu bozukluğun patofizyolojisinianlamaya yönelik yapılan çalışmalarda, oksidatifstres, inflamasyon ve nörotrofik faktörler çokça çalışılmış-tır. Bu çalışmalarda bulgular farklılık gösterse de oksidatifstres, inflamatuar ve nörotrofik faktör biyobelirteçlerindeönemli bulgular elde edilmiştir. Bu derlemede ikiuçlubozukluğun karakteristik dönemlerinden birisi olan manikdönemde serum veya plazmada çalışılan oksidatif stres,inflamasyon ve nörotrofik faktör biyobelirteçleri üzerindedurulacaktır.

PDF

___

1. Kastrup MC, Ramos AB. Global mental health. Dan Med Bull. 2007;54(1):42-3.
2. Scola G, Andreazza AC. Current state of biomarkers in bipolar disorder. Curr Psychiatry Rep. 2014;16(12):514. [CrossRef]
3. Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218(1-2):61-8. [CrossRef]
4. Teixeira AL, Barbosa IG, Machado-vieira R, Rizzo LB, Wieck A, Bauer ME. Novel biomarkers for bipolar disorder. Expert Opin Med Diagn. 2013;7(2):147-59. [CrossRef]
5. Schwarz E, Bahn S. The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br J Pharmacol. 2008;153(Suppl1):S133-6. [CrossRef]
6. Roda Â, Chendo I, Kunz M. Biomarkers and staging of bipolar disorder: a systematic review. Trends Psychiatry Psychother. 2015;37(1):3-11. [CrossRef]
7. Berk M, Kapczinskie F, Andreazzae AC, Deana OM, Giorlando F, Maesg M, et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-17. [CrossRef]
8. Gergerlioglu HS, Savas HA, Bulbul F, Selek S, Uz E, Yumru M. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):697-702. [CrossRef]
9. Savaş H, Herken H, Yürekli M, Uz E, Tutkun H, Zoroğlu SS, et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology. 2002;45(2):57-61. [CrossRef]
10. Yanik M, Vural H, Tutkun H, Zoroglu SS, Savaş HA, Herken H, et al. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci. 2004;254(1):43-7. [CrossRef]
11. Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J. 1966;99(3):667-76. [CrossRef]
12. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V Jr, da Silva Vargas R, etl al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett. 2007;421(1):33-6. [CrossRef]
13. Frey BN, Andreazza AC, Kunz M, Gomes FA, Quevedo J, Salvador M, et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1):283-5. [CrossRef]
14. Kunz M, Gama CS, Andreazza AC, Salvador M, Cereser KM, Gomes FA, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(7):1677-81. [CrossRef]
15. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res. 2007;41(6):523-9. [CrossRef]
16. Tsai MC, Huang TL. Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord. 2015;173:22-6. [CrossRef]
17. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, KauerSant’Anna M, Klamt F, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45(2):156-61. [CrossRef]
18. Andreazza AC, Kauer-Sant’anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111(2-3):135-44. [CrossRef]
19. Bulut M, Altindag A, Deveci Z, Kaya MC, Bulbul F, Taskin A, et al. Oxidative parameters in bipolar patients treated with electroconvulsive therapy and pharmacotheraphy. Journal of Mood Disorders (JMOOD) 2013;3(3):93-9. [CrossRef]
20. Kalelioglu T, Genc A, Karamustafalioglu N, Tasdemir A, Can Gungor F, Cansiz A, et al. Initial and post-treatment total oxidantantioxidant status and oxidative stress index in male patients with manic episode. Psychiatry Res. 2014;218(1-2):249-51. [CrossRef]
21. Nakamura H. Thioredoxin and its related molecules: update 2005. Antioxid Redox Signal. 2005;7(5-6):823-8. [CrossRef]
22. Genc A, Kalelioglu T, Karamustafalioglu N, Tasdemir A, Gungor FC, Genc ES, et al. Level of plasma thioredoxin in male patients with manic episode at initial and post-electroconvulsive or antipsychotic treatment. Psychiatry Clin Neurosci. 2015;69:(6)344- 50. [CrossRef]
23. Sharma AN, Bauer IE, Sanches M, Galvez JF, Zunta-Soares GB, Quevedo J, et al. Common biological mechanisms between bipolar disorder and type 2 diabetes: Focus on inflammation. Prog Neuropsychopharmacol Biol Psychiatry. 2014;54:289-98. [CrossRef]
24. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’anna M, Mascarenhas M, Escosteguy Vargas A, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009;116(3):214-7. [CrossRef]
25. Kim YK, Jung HG, Myint AM, Kim H, Park SH. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007;104(1-3):91-5. [CrossRef]
26. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 1995;29(2):141-52. [CrossRef]
27. Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord. 2001;64(2-3):185-93. [CrossRef]
28. Bai YM, Su TP, Tsai SJ, Wen-Fei C, Li CT, Pei-Chi T, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord. 2014;166:187-92. [CrossRef]
29. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry. 2002;7(10):1107-14. [CrossRef]
30. Kim YK, Myint AM, Lee BH, Han CS, Lee SW, Leonard BE, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004;129(3):267-72. [CrossRef]
31. Ortiz-Domínguez A, Hernández ME, Berlanga C, GutiérrezMora D, Moreno J, Heinze G, et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007;9(6):596-602. [CrossRef]
32. O’Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 2006;90(2-3):263-7. [CrossRef]
33. Barbosa IG, Huguet RB, Mendonça VA, Sousa LP, Neves FS, Bauer ME, et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2011;261(12):139-43. [CrossRef]
34. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45(12):1608-16. [CrossRef]
35. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord. 2012;136(1-2):110-6. [CrossRef]
36. Tsai SY, Lee CH, Huang SH, Chung KH, Chen PH. Soluble interleukin-6 receptor level reflecting the illness activity in bipolar disorder. Aust N Z J Psychiatry. 2014;48(4):382-3. [CrossRef]
37. Liu HC, Yang YY, Chou YM, Chen KP, Shen WW, Leu SJ. Immunologic variables in acute mania of bipolar disorder. J Neuroimmunol. 2004;150(1-2):116-22. [CrossRef]
38. Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS. Assessment of cytokine levels and hs-CRP in bipolar I disorder before and after treatment. Psychiatry Res. 2015;228(3):386-92. [CrossRef]
39. Li H, Hong W, Zhang C, Wu Z, Wang Z, Yuan C, et al. IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J Affect Disord. 2015;174:361-6. [CrossRef]
40. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(4):952-5. [CrossRef]
41. Munkholm K, Weikop P, Kessing LV, Vinberg M. Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav Immun. 2015;43:205-13. [CrossRef]
42. Kalelioglu T, Akkus M, Karamustafalioglu N, Genc A, Genc ES, Cansiz A, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as inflammation markers for bipolar disorder. Psychiatry Res. 2015;228(3):925-7. [CrossRef]
43. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144(1-2):16-27. [CrossRef]
44. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37(12):1553-61. [CrossRef]
45. Fernandes BS, Molendijk ML, Köhler CA, Soares JC, Leite CM, Machado-Vieira R, et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med. 2015;13:289. [CrossRef]
46. Barbosa IG, Huguet RB, Mendonça VA, Neves FS, Reis HJ, Bauer ME, et al. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci Lett. 2010;475(2):95-8. [CrossRef]
47. Barbosa IG, Rocha NP, Miranda AS, Huguet RB, Bauer ME, Reis HJ, et al. Increased BDNF levels in long-term bipolar disorder patients. Rev Bras Psiquiatr. 2013;35(1):67-9. [CrossRef]
48. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology. 2014;47:199-211. [CrossRef]
49. Barbosa IG, Morato IB, Huguet RB, Rocha FL, Machado-Vieira R, et al. Decreased plasma neurotrophin-4/5 levels in bipolar disorder patients in mania. Rev Bras Psiquiatr. 2014;36(4):340-3. [CrossRef]
50. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Gonçalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398(3):215-9. [CrossRef]
51. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry. 2007;61(2):142-4. [CrossRef]
52. de Oliveira GS, Ceresér KM, Fernandes BS, Kauer-Sant’Anna M, Fries GR, Stertz L, et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res. 2009;43(14):1171-4. [CrossRef]
53. Rabie MA, Mohsen M, Ibrahim M, El-Sawy Mahmoud R. Serum level of brain derived neurotrophic factor (BDNF) among patients with bipolar disorder. J Affect Disord. 2014;162:67-72. [CrossRef]
54. Tramontina JF, Andreazza AC, Kauer-Sant’anna M, Stertz L, Goi J, Chiarani F, Kapczinski F. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett. 2009;452(2):111-3. [CrossRef]
55. Tunca Z, Kıvırcık Akdede B, Özerdem A, Alkın T, Polat S, Ceylan D, et al. Diverse glial cell line-derived neurotrophic factor (GDNF) support between mania and schizophrenia: a comparative study in four major psychiatric disorders. Eur Psychiatry. 2015;30(2):198- 204. [CrossRef]
56. Yoshimura R, Nakano Y, Hori H, Ikenouchi A, Ueda N, Nakamura J. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol. 2006;21(7):433-8. [CrossRef]
57. Grande I, Kapczinski F, Stertz L, Colpo GD, Kunz M, Cereser KM, et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder. J Psychiatr Res. 2012;46(11):1511-4. [CrossRef]
58. Huang TL, Hung YY, Lee CT, Chen RF. Serum protein levels of brainderived neurotrophic factor and tropomyosin-related kinase B in bipolar disorder: effects of mood stabilizers. Neuropsychobiology. 2012;65(2):65-9. [CrossRef]
59. de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett. 2011;494(1):54-6. [CrossRef]
60. Karamustafalioglu N, Genc A, Kalelioglu T, Tasdemir A, Umut G, Incir S, et al. Plasma BDNFs level initially and post treatment in acute mania: comparison between ECT and atypical antipsychotic treatment and healthy controls. J Psychopharmacol. 2015;29(8):898-902. [CrossRef]
61. Albert U, De Cori D, Aguglia A, Barbaro F, Bogetto F, Maina G. Increased uric acid levels in bipolar disorder subjects during different phases of illness. J Affect Disord. 2015;173:170-5. [CrossRef]
62. Turan T, Uysal C, Asdemir A, Kiliç E. May oxytocin be a trait marker for bipolar disorder? Psychoneuroendocrinology. 2013;38(12):2890-6. [CrossRef]
63. Emul M, Karamustafalioglu N, Kalelioglu T, Genc A, Tasdemir A, Gungor FC, et al. The nesfatin 1 level in male patients with manic episode and alterations of nesfatin 1 level after antipsychotic and electroconvulsive treatment. J Affect Disord. 2013;151(3):849-53. [CrossRef]
64. Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, Colpo GD, Stertz L, Panizzutti B, et al. Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev Neurother. 2013;13(7):827-42. [CrossRef]